Actively Recruiting
TDCS to Improve Post-Stroke Cognitive Impairment
Led by Johns Hopkins University · Updated on 2025-09-16
60
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
Sponsors
J
Johns Hopkins University
Lead Sponsor
U
University of Maryland, College Park
Collaborating Sponsor
AI-Summary
What this Trial Is About
The investigators will conduct a randomized, double-blinded, sham-controlled trial of approximately 60 patients with minor stroke and post-stroke mild cognitive impairment (psMCI). Participants will be individually randomized on enrollment using a random number generator to treatment with anodal tDCS + computerized cognitive treatment (CCT) versus sham + CCT (approximately 30 patients in each arm). Clinical evaluation including assessment of cognition will be performed pre- and post-intervention by individuals on the study team blinded to the participant's intervention. Participants will also undergo functional neuroimaging with magnetoencephalography (MEG) pre- and post-intervention (1, 3, and 6 months post-stroke to evaluate for initial and longer-term effects of treatment on cerebral activation patterns and functional connectivity). Neuroimaging and clinical outcomes will be assessed to determine the effect of tDCS versus sham + CCT on psMCI.
CONDITIONS
Official Title
TDCS to Improve Post-Stroke Cognitive Impairment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years or older with neurological symptoms from an acute ischemic stroke occurring within the week before hospital admission
- Evidence of acute ischemic stroke on brain MRI (no negative strokes or transient ischemic attacks)
- Native English speaker before the stroke
- NIH Stroke Scale score less than 8 at about 30 days after stroke
- Modified Rankin Scale score between 0 and 2 at about 30 days after stroke
You will not qualify if you...
- Primary intracerebral hemorrhage shown by blood on head CT or MRI
- Presence of a proximal large vessel occlusion
- Cortical exam signs such as aphasia or neglect
- History of dementia or untreated psychiatric illness
- Uncorrected hearing or vision loss
- Unable to attend treatment or follow-up visits
- Unable to travel to College Park (UMD) for MEG scans
- Presence of devices or implants causing interference with MEG (e.g., pacemaker, intracranial clips, metal implants near the head or eyes)
- Claustrophobia, obesity, or other conditions preventing staying in the MEG machine for up to one hour
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States, 21224
Actively Recruiting
Research Team
E
Elisabeth B Marsh, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here